Sharps Technology’s $400 million raise will fund a Solana treasury that converts corporate cash into SOL exposure through a PIPE deal and pre-funded warrants. The move — including a $50M SOL purchase at a 15% discount — propelled Sharps stock up 96% intraday and signals growing health-sector interest in crypto treasuries.
-
Sharps announced a $400M raise to build a Solana treasury, buying $50M in SOL via a PIPE at 15% discount.
-
Shares surged 96% intraday, reflecting investor appetite for crypto-exposed corporate balance sheets.
-
Executives include Alice Zhang as CIO; the deal uses locked or unlocked SOL with stapled warrants and closes around Aug. 28, 2025.
Sharps Technology Solana treasury: $400M raise to build a SOL treasury and reshape its balance sheet — read details and implications for health-sector crypto treasuries.
What is the Sharps Technology Solana treasury move?
Sharps Technology Solana treasury refers to the company’s plan to convert corporate capital into Solana (SOL) exposure by raising $400 million and executing a PIPE that includes a $50 million SOL purchase at a 15% discount. The announcement sent Sharps shares up 96% intraday and marks a notable health-sector pivot into crypto treasuries.
How will the PIPE deal and SOL purchase work?
The PIPE (private investment in public equity) allows accredited investors to buy discounted shares, funding the treasury initiative. Sharps agreed to acquire $50 million in SOL at a 15% discount to a 30-day average price, with the transaction expected to close on or around Aug. 28, 2025.
Investors may contribute locked or unlocked SOL and will receive pre-funded, stapled warrants. This structure directly ties equity exposure to SOL performance while providing upfront funding for the corporate treasury.
Sharps Technology intraday performance on Nasdaq. Source: Yahoo Finance
Why are health sector firms shifting to crypto treasuries?
Health companies are pursuing crypto treasuries to diversify balance sheets and attract investor attention amid weak core business performance. The strategy is marketed as a potential inflation hedge and a way to unlock new capital sources for cash-hungry drug development or device rollouts.
Examples include Hoth Therapeutics’ $1M Bitcoin allocation (Nov. 2024), Atai Life Sciences’ $5M Bitcoin purchase (Mar. 2025), and 180 Life Sciences’ rebrand to ETHZilla with plans for a large Ether treasury after severe stock declines.
Frequently Asked Questions
Will Sharps keep operating cash separate from the Solana treasury?
Yes. Companies typically segregate operational cash from treasury allocations to preserve liquidity for core business needs while designating a separate balance sheet allocation for crypto assets and associated warrants.
Is the Solana treasury strategy risky for shareholders?
There is elevated volatility risk since SOL is historically more volatile than fiat or traditional assets. Financial disclosures and independent custody arrangements are essential to manage valuation, reporting, and governance risks.
Related: Galaxy Digital, Multicoin, Jump Crypto plan $1B Solana fund: Report
Magazine: Asia Express: ‘China’s MicroStrategy’ Meitu sells all its Bitcoin and Ethereum
Key Takeaways
- Strategic shift: Sharps is reallocating capital to a Solana-focused treasury to gain crypto exposure.
- Deal specifics: $400M raise, $50M SOL purchase at 15% discount, PIPE structure with stapled warrants.
- Investor implications: Immediate stock rally shows market interest, but volatility and governance risks remain.
Conclusion
The Sharps Technology Solana treasury announcement is a clear signal that some health-sector firms are exploring crypto treasuries to diversify balance sheets and attract investor interest. Investors should weigh potential rewards against volatility and disclosure practices. COINOTAG will monitor closing updates and reporting as the deal progresses; investors should review company filings and official statements for confirmation.
